|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0009429,
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0059985,
umls-concept:C0205390,
umls-concept:C0332283,
umls-concept:C0383429,
umls-concept:C0393022,
umls-concept:C0556895,
umls-concept:C0855095,
umls-concept:C1516224,
umls-concept:C1708063
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-3-10
|
|
pubmed:abstractText |
The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2008 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1288-95
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18189296-Adult,
pubmed-meshheading:18189296-Aged,
pubmed-meshheading:18189296-Aged, 80 and over,
pubmed-meshheading:18189296-Antibodies, Monoclonal,
pubmed-meshheading:18189296-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18189296-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18189296-Antibodies, Neoplasm,
pubmed-meshheading:18189296-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18189296-Disease-Free Survival,
pubmed-meshheading:18189296-Female,
pubmed-meshheading:18189296-Humans,
pubmed-meshheading:18189296-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:18189296-Male,
pubmed-meshheading:18189296-Maximum Tolerated Dose,
pubmed-meshheading:18189296-Middle Aged,
pubmed-meshheading:18189296-Survival Rate,
pubmed-meshheading:18189296-Vidarabine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
|
|
pubmed:affiliation |
Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA. jhainsworth@tnonc.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
